|
Post by porkini on Oct 30, 2018 10:02:36 GMT -5
Do you have a link for that? My convoluted logic... I don't do anything for mnkd at this point, so, I am equal to RLS! NOT! Link is the rls PR. Where does it state milestone to mnkd? So you are just bent out of shape because the actual PR did not mention it? Maybe you should be on their payroll and writing their PR's then? Let's pay attention, this is pretty easy: www.receptorlife.com/receptor-enters-into-collaboration-and-license-agreement-with-mannkind
|
|
|
Post by mnkdfann on Oct 30, 2018 11:02:08 GMT -5
So you think a fund raise counts as a product development milestone? "MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product." Milestones in time, indubitably, but for a fund raise? I would be surprised.
|
|
|
Post by mike0475 on Oct 30, 2018 11:24:52 GMT -5
my point exaclty. I'm not bent out of shape even though one assumes it. I was simply pointing out this RLS update does not at the moment note any sort of financial change toward MNKD. Not saying its not coming at all. I also like the timing of call and this PR.
|
|
|
Post by awesomo on Oct 30, 2018 11:25:14 GMT -5
This definitely signals that RLS isn't some fly-by-night company, but lets not jump the gun here. Until we have more visibility into their product roadmap, we can assume we are still a long ways off from any sort of milestone payments from the license agreement.
|
|
|
Post by Clement on Oct 30, 2018 12:01:32 GMT -5
Fun facts from Yahoo finance today:
forward PE MNKD -2.67 GWPH -29.95
price/sales MNKD 20.31 GWPH 255.43
enterprise value / revenue MNKD 28.86 GWPH 206.46
Maybe RLS can connect us with some of that blue sky.
|
|
|
Post by markado on Oct 30, 2018 12:04:28 GMT -5
Milestones is plural. And, we know that MNKD has agreed to fees of $10M to develop another molecule for UTHR. What's to say there isn't such an agreement or a similar agreement in place for RLS, within the $100M+? Maybe we will get more on Thursday. But that we have 3-4 molecules in motion or play is exciting. Think about this...Amazon is a platform for e-commerce of many kinds...MNKD is a platform for medicines of many kinds. Being the platform can be an enviable place to be. Keeping the platform intact while you grow can be the challenge.
|
|
|
Post by cjc04 on Oct 30, 2018 12:06:58 GMT -5
To help stir the pot a bit, while Andrea Leone Bay is a RLS employee, my guess is she works full time at the Mannkind facility in Danbury. When she first went to RLS, she changed her LinkedIn profile for a bit showing Seattle and then it went back to greater NYC. you're not stirring pot, it’s obvious. When the RLS deal was announced they said they’d be doing their work at the Mannkind facility. Where else would she have been working, at a PO box in Seattle? Where the heck is “dreamboatcruise” he loved to fight me on this issue.
|
|
|
Post by sportsrancho on Oct 30, 2018 12:10:05 GMT -5
To help stir the pot a bit, while Andrea Leone Bay is a RLS employee, my guess is she works full time at the Mannkind facility in Danbury. When she first went to RLS, she changed her LinkedIn profile for a bit showing Seattle and then it went back to greater NYC. you're not stirring pot, it’s obvious. When the RLS deal was announced they said they’d be doing their work at the Mannkind facility. Where else would she have been working, at a PO box in Seattle? Where the heck is “dreamboatcruise” he loved to fight me on this issue. You won:-))
|
|
|
Post by peppy on Oct 30, 2018 12:11:51 GMT -5
Fun facts from Yahoo finance today: forward PE MNKD -2.67 GWPH -29.95 price/sales MNKD 20.31 GWPH 255.43 enterprise value / revenue MNKD 28.86 GWPH 206.46 clement since you looked, I wonder what GWPH debt situation is? These comparisons are very confusing to me. In development the hopeful investors are there? Then the product. Will it sell? RLS is the GWPH comparable market.
|
|
|
Post by porkini on Oct 30, 2018 12:19:16 GMT -5
So you think a fund raise counts as a product development milestone? "MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product." Milestones in time, indubitably, but for a fund raise? I would be surprised. So you think that I said a fund raise counts as a product development milestone? Wow, I see that as completely delusional, and I did reread my posts on this thread. Good and positive news was posted about RLS and I proceeded to point out the information where RLS had entered into a collaboration and license agreement with MNKD ( www.receptorlife.com/receptor-enters-into-collaboration-and-license-agreement-with-mannkind). Sorry if you missed that or are twisting something to put negative spin on this. I have to agree with awesomo who put it very simply: This definitely signals that RLS isn't some fly-by-night company, but lets not jump the gun here. Until we have more visibility into their product roadmap, we can assume we are still a long ways off from any sort of milestone payments from the license agreement.
|
|
|
Post by Clement on Oct 30, 2018 12:26:38 GMT -5
Pep, fun facts. Although MNKD is not directly in the pot business, we are connected through RLS so I thought it would be fun to take a look.
MNKD debt and cash figures are sorely out of date on Yahoo finance.
|
|
|
Post by mnkdfann on Oct 30, 2018 12:31:40 GMT -5
So you think a fund raise counts as a product development milestone? "MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product." Milestones in time, indubitably, but for a fund raise? I would be surprised. So you think that I said a fund raise counts as a product development milestone? Wow, I see that as completely delusional, and I did reread my posts on this thread. Good and positive news was posted about RLS and I proceeded to point out the information where RLS had entered into a collaboration and license agreement with MNKD ( www.receptorlife.com/receptor-enters-into-collaboration-and-license-agreement-with-mannkind). Sorry if you missed that or are twisting something to put negative spin on this. I have to agree with awesomo who put it very simply: This definitely signals that RLS isn't some fly-by-night company, but lets not jump the gun here. Until we have more visibility into their product roadmap, we can assume we are still a long ways off from any sort of milestone payments from the license agreement. To be honest, I now have no idea what your original point was. You seemed to be arguing with mike0475 who said the fund raise wouldn't equal a milestone payment. You provided a link and seemed to be making the point that a milestone was now due. If I misread your post, my bad, but I wasn't the only one. If you are agreeing with awesomo that a milestone is still a long ways off (as you appear to be), then we are on the same page.
|
|
|
Post by mango on Oct 30, 2018 13:03:35 GMT -5
So yeah...I'm like bouncing around the room here at work.
|
|
|
Post by comnkd on Oct 30, 2018 13:10:07 GMT -5
So yeah...I'm like bouncing around the room here at work. Ha! This news is exciting indeed that I just gotta... youtu.be/eHQchXAbjy0
|
|
|
Post by cppoly on Oct 30, 2018 13:28:57 GMT -5
Also from the website:
"Mr. Wesner managed an exhaustive analysis of worldwide pulmonary drug delivery technologies and became convinced MannKind’s inhalation system is the only one capable of safely, reliably and precisely delivering cannabinoid-based drugs rapidly to the bloodstream. That insight led to Receptor and MannKind’s global partnership."
|
|